Oct 30,2024 TOP STORY

Beta Bionics Announces Launch of the iLet Bionic Pancreas with Abbott’s FreeStyle Libre 3 Plus sensor

Beta Bionics has launched its iLet Bionic Pancreas integrated with Abbott's FreeStyle Libre 3 Plus sensor, providing fully autonomous insulin delivery for people with diabetes. The iLet calculates insulin doses using minute-by-minute glucose data from the sensor, removing the need for carb counting or manual insulin corrections. Beta Bionics also released the Bionic Circle App, allowing up to 10 family members or friends to remotely monitor users’ glucose levels and insulin doses. This integration offers a new approach to diabetes management with convenient access through pharmacies and a pay-as-you-go model.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 30,2024 TOP STORY

ABBOTT'S FREESTYLE LIBRE® 2 AND 3: FIRST CONTINUOUS GLUCOSE MONITORING SYSTEMS APPROVED FOR USE DURING MEDICAL IMAGING

Abbott announced that its FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems have received FDA clearance for use during common imaging procedures like X-rays, CT scans, and MRIs, making them the first CGM systems approved for this use. Previously, patients had to remove and discard their CGM sensors before imaging, causing data gaps and added costs. The updated clearance allows patients to maintain continuous glucose monitoring throughout these procedures, supporting uninterrupted diabetes management and improving convenience and affordability. Abbott’s rigorous testing ensured sensor efficacy post-imaging, reflecting its dedication to accessible diabetes care innovations.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 24,2024

Dexcom Reports Third Quarter 2024 Financial Results

DexCom, Inc. reported a 2% year-over-year increase in third-quarter 2024 revenue, totaling $994.2 million, with international sales showing strong growth at 12% while U.S. revenue declined by 2%. Despite a dip in GAAP operating income, Dexcom saw a GAAP net income increase to $134.6 million or $0.34 per diluted share. Key highlights included the U.S. launch of Stelo, a biosensor for prediabetes and Type 2 diabetes management, and the international release of Dexcom G7 and Dexcom ONE+ in Australia and France, respectively. Dexcom reiterated its annual guidance and announced a $750 million share repurchase. The company’s financial position remains strong, with $2.49 billion in liquidity.

View Analyst & Ambassador Comments
Go to original news
Aug 12,2024

Blood Glucose Monitoring Devices Market size is set to grow by USD 8.70 billion from 2024-2028, Rising global burden of diabetes to boost the market growth, Technavio

The global blood glucose monitoring devices market is projected to grow by $8.7 billion from 2024 to 2028 at a CAGR of 9.45%, driven by the increasing prevalence of diabetes worldwide and a shift towards convenient, smartwatch-based monitoring applications. This trend reflects a preference for wearable, real-time glucose management tools that integrate continuous glucose monitoring (CGM) directly into everyday devices, enhancing ease of use and accessibility for users. Leading companies such as Abbott, Medtronic, and Dexcom are expanding offerings in both hospital and home-care segments, focusing on innovations in glucose meters, insulin pumps, and CGM systems.

#bgm

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 23,2024

Ypsomed and BD collaborate to advance self-injection systems for high viscosity biologics

Ypsomed has partnered with BD (Becton, Dickinson and Company) to enhance self-injection options for high-viscosity biologic drugs through a new integration. Their collaboration combines BD’s Neopak XtraFlow Glass Prefillable Syringe with Ypsomed’s YpsoMate 2.25 autoinjector, allowing for the efficient delivery of biologics with viscosities over 15cP. The innovative syringe features a shorter, 8-millimeter needle and thinner walls to support easier, more effective subcutaneous injections, while Ypsomed has adapted its autoinjector for optimal compatibility. This development promises to accelerate drug delivery options for pharmaceutical companies, ultimately providing patients with easier, safer self-administration for complex biologic therapies.

COLLABORATION PARTNERSHIP
View Analyst & Ambassador Comments
Go to original news
Sep 05,2024

Utilizing Continuous Glucose Monitoring for Early Detection of Gestational Diabetes Mellitus and Pregnancy Outcomes in an Asian Population

A study of 103 overweight or obese Asian women in early pregnancy found that continuous glucose monitoring (CGM) may effectively predict gestational diabetes mellitus (GDM) and adverse pregnancy outcomes, such as primary cesarean delivery and larger-than-average newborns. CGM-derived metrics outperformed traditional risk models in predicting GDM, suggesting that CGM could be valuable in early pregnancy screenings to improve outcomes for high-risk pregnancies.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 23,2024

Netherlands Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring Dexcom, Medtronic, Roche, Abbott Laboratories, Eli Lilly, Terumo, & BD

The Netherlands' diabetes device market is projected to grow from $343.4 million in 2023 to $641.7 million by 2032, driven by an aging population, increased diabetes prevalence, and rising demand for remote monitoring solutions. With technological advances and government health initiatives, devices like insulin delivery systems and continuous glucose monitors are increasingly vital for disease management. Remote monitoring, facilitated by continuous glucose monitors and health apps, allows for proactive diabetes care and reduces the need for in-person consultations. Key players in this market include Dexcom, Medtronic, Roche, and Abbott Laboratories.

#cgm

#bgm

#insulin pump

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Sep 26,2024

Mobile phone interventions to improve health outcomes among patients with chronic diseases: an umbrella review and evidence synthesis from 34 meta-analyses

An umbrella review analyzed 34 meta-analyses from 235 randomized controlled trials across 52 countries, involving nearly 49,000 participants with ten chronic conditions, to assess the effectiveness of mobile phone interventions. The findings revealed that mobile apps significantly reduced glycated hemoglobin in adults with type 2 diabetes. Text messages and apps also showed strong positive effects on medication adherence in HIV patients and cardiovascular disease management, as well as improvements in glucose management and blood pressure reduction. However, 42% of the analyzed effects were non-significant, highlighting the need for further research. Key gaps identified included limited studies from low-income countries, inadequate reporting of adverse events, and the challenge of inconsistent conclusions across existing reviews. The study underscores the potential of mobile health technology to improve chronic disease management but also calls for enhanced methodological rigor in future research.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 23,2024

Japan Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring Abbott Laboratories, Roche, Medtronic, Novo Nordisk, Terumo, Eli Lilly, BD, and Dexcom

The Japan Diabetes Device Market is projected to grow significantly, reaching $2.8 billion by 2032, driven by a 7.49% annual growth rate. Key factors include government-supported health initiatives by the Ministry of Health, Labour and Welfare (MHLW), which emphasize early diabetes detection and subsidize devices like insulin pumps and continuous glucose monitors (CGMs). National awareness campaigns also increase understanding of diabetes prevention, encouraging broader adoption of advanced monitoring technologies. Companies such as Abbott, Roche, Medtronic, and Dexcom are expected to play major roles in this expanding market.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 21,2024

Disposable Medical Sensors Market to Reach $18.15 Billion, Globally, by 2032 at 8.4% CAGR

The global disposable medical sensors market is projected to grow from $8.1 billion in 2022 to $18.15 billion by 2032, at a compound annual growth rate (CAGR) of 8.4%. This growth is driven by the increasing demand for remote patient monitoring systems and heightened awareness of infection control in healthcare settings. Disposable sensors enhance patient care by enabling real-time monitoring of vital signs, allowing for timely medical interventions and improved outcomes. Recent technological advancements have enhanced the efficiency and usability of these sensors, making them integral in modern healthcare delivery. The market's expansion is particularly pronounced in developing countries, where cost-effective disposable sensors help healthcare facilities upgrade their technologies without significant financial burdens. By prioritizing hygiene and patient safety, the adoption of disposable medical sensors is set to continue rising, reflecting a broader commitment to improving healthcare standards globally.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES